Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRIMAQUINE vs Artemether-Lumefantrine
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.
Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.
Radical cure of Plasmodium vivax and Plasmodium ovale malaria (FDA-approved),Prophylaxis of Plasmodium vivax relapse following treatment of acute infection
Treatment of uncomplicated malaria due to Plasmodium falciparum,Treatment of chloroquine-resistant malaria
15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.
Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.
Terminal elimination half-life of approximately 4-7 hours; in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, half-life may be prolonged due to accumulation in erythrocytes
Artemether: terminal elimination half-life approximately 1–2 hours. Dihydroartemisinin: approximately 1–2 hours. Lumefantrine: terminal elimination half-life 4–5 days (range 2–6 days) in patients with uncomplicated malaria; prolonged half-life contributes to post-treatment prophylaxis but may lead to accumulation with repeated dosing.
Primaquine is metabolized primarily by CYP1A2 and CYP3A4; also undergoes monoamine oxidase (MAO) metabolism. Metabolites include primaquine carboxy metabolite.
Artemether is metabolized by CYP3A4 to dihydroartemisinin. Lumefantrine is metabolized by CYP3A4.
Primarily renal (60-65% as unchanged drug and metabolites); small amounts in feces (<5%)
Primarily fecal (biliary) elimination of unchanged drug and metabolites; renal excretion is negligible (<1% for artemether and <0.1% for lumefantrine). Artemether is extensively metabolized by CYP3A4/5 to dihydroartemisinin, which is further glucuronidated and excreted in bile. Lumefantrine is metabolized by CYP3A4 to desbutyl-lumefantrine; both parent and metabolite are eliminated via feces.
Approximately 90-95% bound to plasma proteins, primarily to albumin
Artemether: 95% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Dihydroartemisinin: 93% bound. Lumefantrine: >99% bound to high-density lipoproteins (HDL) and, to a lesser extent, to albumin and α1-acid glycoprotein.
Apparent volume of distribution (Vd) approximately 2.5-3.5 L/kg, indicating extensive tissue distribution, including high concentrations in erythrocytes and liver, which is relevant for anti-relapse activity
Artemether: Vd approximately 2–5 L/kg, indicating extensive tissue distribution. Dihydroartemisinin: Vd 0.5–1.5 L/kg. Lumefantrine: Vd extremely large, ranging from 10–30 L/kg (reported up to 31 L/kg), reflecting extensive tissue binding and accumulation in erythrocytes and organs (liver, lung, kidney).
Oral bioavailability is approximately 96%, with peak plasma concentrations reached within 1-3 hours
Oral bioavailability: Artemether is 30–40% due to extensive first-pass metabolism by CYP3A4/5 to dihydroartemisinin, which has 80% oral bioavailability. Lumefantrine has highly variable and food-dependent bioavailability; absorption increases 2–16 fold when taken with a high-fat meal. Bioavailability is approximately 5–10% in the fasted state and up to 85% when administered with fat-containing food. The combination is formulated to enhance lumefantrine absorption with a fixed ratio of artemether:lumefantrine 1:6.
No specific dose adjustment recommended for renal impairment; use with caution in severe renal impairment due to potential accumulation.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
Contraindicated in severe hepatic impairment; use with caution in mild-to-moderate impairment, reduce dose by 50% in Child-Pugh B, avoid in Child-Pugh C.
No dose adjustment for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); avoid use.
0.3 mg/kg (base) orally once daily for 14 days; maximum 15 mg/day.
Weight-based dosing: 5-<15 kg: 1 tablet per dose; 15-<25 kg: 2 tablets per dose; 25-<35 kg: 3 tablets per dose; ≥35 kg: 4 tablets per dose. Administer at 0, 8, 24, 36, 48, and 60 hours. Crush tablets if needed for children <5 kg.
No specific dose adjustment, but monitor for hemolytic effects due to age-related decline in G6PD activity.
No specific dose adjustment required. Monitor for QT prolongation and electrolyte disturbances due to potential age-related decline in cardiac conduction.
Primaquine can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Screen all patients for G6PD deficiency before prescribing.
None
Hemolytic anemia in G6PD deficiency – screen and monitor,Methemoglobinemia – monitor for signs especially in infants and G6PD-deficient patients,QT interval prolongation – use with caution with other QT-prolonging drugs,Hematologic toxicity – monitor CBC in prolonged therapy
QT interval prolongation,Arrhythmias,Recrudescence of infection,Hypersensitivity reactions,Use in hepatic impairment
G6PD deficiency (absolute),Concurrent use of quinacrine (due to increased toxicity),Pregnancy (safe alternative not established; risk of hemolysis in G6PD-deficient fetus),Lactation if infant is G6PD deficient
Hypersensitivity to artemether or lumefantrine,Severe malaria,Pregnancy (first trimester) unless no other option
Take with food to reduce gastrointestinal irritation. No specific food restrictions, but avoid alcohol as it may increase risk of adverse effects.
High-fat meal increases absorption; grapefruit juice may increase lumefantrine levels; avoid concurrent use.
Primaquine crosses the placenta. In the first trimester, fetal G6PD deficiency increases risk of hemolytic anemia. Second and third trimesters: potential for fetal methemoglobinemia. Risk of hemolysis in G6PD-deficient fetuses; contraindicated in pregnancy except for severe malaria treatment when no alternatives exist.
FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and third trimester: limited human data but appears safe; no increased risk of congenital malformations reported. Use only if benefit outweighs risk.
Primaquine is excreted into breast milk in small amounts. M/P ratio not established. Risk of hemolysis in G6PD-deficient infants. Avoid breastfeeding in women with infant G6PD deficiency; use caution.
Both artemether and lumefantrine are excreted in breast milk in low amounts. M/P ratio: artemether ~0.3, lumefantrine ~0.5. Considered compatible with breastfeeding; no adverse effects observed in infants. Use caution if infant has G6PD deficiency due to theoretical risk of hemolysis.
Pregnancy reduces primaquine exposure via increased clearance; however, due to teratogenicity and hemolytic risk, dosing adjustments are not recommended; alternative antimalarials preferred.
No dose adjustment required for uncomplicated malaria in second and third trimester. First trimester: avoid unless no alternative; use same weight-based dosing. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) do not mandate dose changes; standard 6-dose regimen over 3 days is recommended.
Primaquine is the only agent active against hypnozoites of Plasmodium vivax and P. ovale, preventing relapse. Screen for G6PD deficiency before use; hemolysis risk. Administer with food to reduce GI upset.
Monitor ECG for QTc prolongation; administer with fatty food to enhance absorption; avoid in patients with severe hepatic impairment; pregnancy category C; caution with CYP3A4 inhibitors or inducers.
Take with food to decrease stomach upset.,Report any signs of hemolysis: dark urine, yellow skin/eyes, fatigue.,Complete full course even if symptoms improve.,Avoid concurrent use with other drugs that cause hemolysis.,Inform your doctor of any history of favism or G6PD deficiency.
Take with a high-fat meal or whole milk to improve absorption.,Complete the full 3-day course even if symptoms improve.,Seek medical attention for signs of severe malaria (e.g., altered consciousness, difficulty breathing).,Avoid grapefruit juice during treatment.,Use effective contraception if of childbearing potential.
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
"Anagrelide, a phosphodiesterase 3 (PDE3) inhibitor used for thrombocythemia, and artemether, an antimalarial artemisinin derivative, both prolong the QT interval by inhibiting cardiac potassium channels (specifically IKr). Concurrent use may result in additive QTc prolongation, increasing the risk of Torsade de Pointes and other ventricular arrhythmias. This risk is particularly relevant in patients with electrolyte imbalances, bradycardia, or pre-existing cardiac disease."
"Acepromazine, a phenothiazine antipsychotic/antiemetic, inhibits cytochrome P450 3A4 (CYP3A4), the primary enzyme responsible for metabolizing the antimalarial artemether. Concomitant administration can lead to significantly reduced clearance of artemether, elevating its plasma concentrations. This may increase the risk of dose-dependent toxicities, including neurotoxicity (e.g., ataxia, seizures) and cardiotoxicity (e.g., QT prolongation)."
"Concomitant administration of thioridazine, a potent CYP2D6 inhibitor, with artemether, a substrate of CYP2D6, can significantly increase the serum concentration of artemether. This elevation may potentiate the antimalarial effect but also heightens the risk of artemether-related adverse effects such as QT prolongation and neurotoxicity. Clinically, this interaction warrants caution due to potential cardiotoxicity and altered drug exposure."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRIMAQUINE vs Artemether-Lumefantrine, answered by our medical review team.
PRIMAQUINE is a Antimalarial that works by Antimalarial agent that eliminates exoerythrocytic forms (hypnozoites) of Plasmodium vivax and P. ovale; also active against gametocytes. Mechanism involves generation of reactive oxygen species via redox cycling, disrupting parasite mitochondrial function.. Artemether-Lumefantrine is a Antimalarial that works by Artemether is rapidly converted to dihydroartemisinin, which produces free radicals that damage parasite proteins and membranes. Lumefantrine inhibits heme detoxification in the parasite food vacuole.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRIMAQUINE and Artemether-Lumefantrine depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRIMAQUINE is: 15 mg (base) orally once daily for 14 days for radical cure of P. vivax and P. ovale; 30 mg (base) orally once daily for 7 days for terminal prophylaxis.. The standard adult dose of Artemether-Lumefantrine is: Oral, 4 tablets (each containing 20 mg artemether and 120 mg lumefantrine) at 0, 8, 24, 36, 48, and 60 hours (total 6 doses). For patients ≥35 kg, alternatively 4 tablets at 0, 8, 24, 36, 48, and 60 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining PRIMAQUINE and Artemether-Lumefantrine. The risk or severity of QTc prolongation can be increased when Primaquine is combined with Lumefantrine. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. PRIMAQUINE is classified as Category D/X. Primaquine crosses the placenta. In the first trimester, fetal G6PD deficiency increases risk of hemolytic anemia. Second and third trimesters: potential for fetal methemoglobinemi. Artemether-Lumefantrine is classified as Category C. FDA Pregnancy Category C. Artemether-lumefantrine is not recommended in the first trimester unless no alternative; animal studies show embryotoxicity at high doses. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.